Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and ...

Bayer announces deal with Kumquat for a pancreatic cancer KRAS inhibitor, plus, promising mRNA vaccine research emerges from ...